Skip to content
Study details
Enrolling now

Proof-of-Concept Trial to Assess the Efficacy and Safety of Fezolinetant in Improving Vasomotor Symptoms in Men With Prostate Cancer Undergoing Androgen Deprivation Therapy

Shehzad Basaria, M.D.
NCT IDNCT06957691ClinicalTrials.gov data as of Apr 2026
Phase

Phase 2

Target enrollment

60

Study length

about 3 years

Ages

40+

Sex

Male only

Locations

1 site in MA

What this study is about

This trial is testing a treatment called fezolinetant to see if it can help men with prostate cancer who are getting androgen deprivation therapy experience fewer hot flashes (vasomotor symptoms). The main questions being answered are whether fezolinetant improves the frequency and severity of hot flashes, whether it causes liver damage, and whether it improves quality of life. Participants will take either fezolinetant or a placebo daily for 4 weeks while visiting the clinic every two weeks for checkups and tests.

Simplified from trial records by PatientMatch.

What you may be asked to do

  • 1.Take Placebo
  • 2.Take fezolinetant - reference formulation

Participation Burden

What's physically and logistically required of participants.

Logistics & Travel
In-person visits

Requires travel to a study site

Physical Intervention
Oral

How treatment is administered

Treatment Assignment
Randomized & Blinded

You may get a placebo/standard care, and you won't know which.

Extracted study details

Pulled from the trial record to show what is being tested and what the study is measuring.

Drug classes

GENITO URINARY SYSTEM AND SEX HORMONES

Drug routes

oral (Oral Tablet)

Endpoints

Primary: Change in the Frequency of Vasomotor Symptoms Through Daily Hot Flash Diary from Baseline to 4 Weeks

Secondary: Change in fatigue, as assessed using the using the Functional Assessment of Chronic Illness Therapy - Fatigue questionnaire, Change in fatigue, as assessed using the using the Hypogonadism Energy Diary questionnaire, Change in glycated hemoglobin (HbA1c) level, Change in inflammatory status, as assessed by measuring high-sensitivity C-reactive protein (hsCRP) levels, Change in overall quality of life, as assessed using the Short Form-36 questionnaire, Change in quality-of-life symptoms related to hot flashes, as assessed using the Hot Flash-Related Daily Interference Scale, Change in sleep quality, as assessed using the Patient-Reported Outcomes Measurement Information System Sleep Disturbance questionnaire

Body systems

Oncology